VectorY Therapeutics: €74.5 Million Financing Advances ALS And Neurodegenerative Disease Pipeline

VectorY Therapeutics has raised €74.5 million, approximately $83.5 million, to advance its clinical and preclinical pipeline of vectorized antibody therapies for neurodegenerative diseases.

New investors Angelini Ventures, Invest-NL and the European Investment Bank joined returning backers Forbion, EQT Life Sciences, MRL Ventures, Insight Partners, BioGeneration Ventures, Eli Lilly and Company, and the ALS Investment Fund.

The financing will support lead candidate VTx-002 through clinical milestones, including the final readout of the PIONEER-ALS Phase 1/2 study. It will also fund additional programs, including VTx-003 for Huntington’s disease.

VTx-002 is designed to target pathological TDP-43, a protein that aggregates abnormally in up to 97% of people with amyotrophic lateral sclerosis. Its vector-based delivery approach is intended to enable sustained antibody expression within the central nervous system.

The therapy remains investigational and has not received regulatory approval.

PIONEER-ALS is a global, multicenter, open-label, dose-escalation study evaluating two dose levels in adults with ALS. Sites are located in the United States, Europe and the United Kingdom.

The study assesses safety, tolerability, pharmacokinetics and exploratory efficacy. Additional measures include neurofilament light chain, TDP-43 pathway-related biomarkers, functional assessments, respiratory measures, muscle strength and survival.

In September 2026, VectorY announced an expansion of the trial from 12 to 36 participants. Enrollment is ongoing.

Beyond ALS and Huntington’s disease, the company’s pipeline includes VTx-004 targeting TDP-43 in frontotemporal dementia and VTx-005 targeting phosphorylated tau in Alzheimer’s disease.

The financing supports both evaluation of the lead program and broader development of the platform, which combines antibody engineering with vector-based delivery and manufacturing capabilities.

KEY QUOTES:

“Neurodegenerative diseases represent some of the most complex challenges in medicine, and patients and families urgently need new treatment options. This financing reflects strong confidence in our team, our platform and the potential of our pipeline. It will support the advancement of VTx-002 through important clinical milestones, including the final readout of PIONEER-ALS, while enabling us to leverage our vectorized antibody platform to expand its application in multiple neurodegenerative diseases across our pipeline. We are grateful for the continued support of our existing investors and welcome our new partners as we work to advance care for patients.”

Jim Scibetta, CEO Of VectorY Therapeutics

“We believe VectorY is building a compelling approach to one of the most challenging areas of medicine. Its progress with VTx-002, including the expansion of the PIONEER-ALS study, is an important step in evaluating the program’s potential. This financing will help the company advance that work while developing additional programs, including VTx-003 for Huntington’s disease. We are pleased to continue supporting VectorY as it translates its platform into potential pioneering treatment options for people living with neurodegenerative diseases.”

Wouter Joustra, General Partner At Forbion